Literature DB >> 28650862

The potential combinational effect of miR-34a with celecoxib in osteosarcoma.

Xia Chen1, Dan Peng, Yi Shen, Bo Liu, Hongkang Zhou, Huai Tao, Jufang Huang.   

Abstract

Advanced osteosarcoma (OS) is usually treated by preoperative and postoperative chemotherapy, but there are a very limited number of active agents. Celecoxib (Cel) is a COX-2-selective nonsteroidal anti-inflammatory drug and its antitumoral effect has been shown widely in a variety of cancers including OS cells in vitro. However, the potential combinational effect of Cel with other biological therapy has not been reported in OS cells. In this study, the effects of Cel, miR-34a mimics, and their combination on cell proliferation (MTT assay), migration (in-vitro scratch assay), invasion (transwell assay), mRNA (real-time PCR), and protein (Western blot) expression of associated signal transductions were investigated in cultured MG63 cells. The results showed that miR-34a mimics transfection and Cel treatment significantly decreased cell viability, migration, and invasion in MG63 cells, with their combination being more effective. In contrast, miR-34a inhibitors transfection exerted an effect opposite to miR-34a mimics on cell viability, migration, and invasion. The antitumoral effects of miR-34a, Cel, and their combination were observed in significant up-regulated expression of PTEN and GSK-3β, down-regulated expression of ROCK1, Notch1, and MMP9 as well as Akt Ser phosphorylation. Our data suggested that miR-34a exerts a combinational effect with Cel on the cell proliferation, migration, and invasion in OS cells through regulating Notch1/ROCK1-PTEN-Akt-GSK-3β signaling and MMP9 gene expression.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28650862     DOI: 10.1097/CAD.0000000000000530

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  9 in total

Review 1.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

Review 2.  Decoding microRNA drivers in atherosclerosis.

Authors:  Tanwi Vartak; Soundharya Kumaresan; Eoin Brennan
Journal:  Biosci Rep       Date:  2022-07-29       Impact factor: 3.976

3.  Change of miRNA expression profiles in patients with knee osteoarthritis before and after celecoxib treatment.

Authors:  Zhao Dong; Honghui Jiang; Xiaofei Jian; Weiguo Zhang
Journal:  J Clin Lab Anal       Date:  2018-08-13       Impact factor: 2.352

Review 4.  The Network of Non-coding RNAs in Cancer Drug Resistance.

Authors:  Fabio Corrà; Chiara Agnoletto; Linda Minotti; Federica Baldassari; Stefano Volinia
Journal:  Front Oncol       Date:  2018-08-29       Impact factor: 6.244

Review 5.  Enhanced Inhibition of Tumorigenesis Using Combinations of miRNA-Targeted Therapeutics.

Authors:  Svetlana Miroshnichenko; Olga Patutina
Journal:  Front Pharmacol       Date:  2019-05-16       Impact factor: 5.988

6.  Notch-1 promotes the malignant progression of osteosarcoma through the activation of cell division cycle 20.

Authors:  Yuan Gao; Lunhao Bai; Guanning Shang
Journal:  Aging (Albany NY)       Date:  2020-12-19       Impact factor: 5.682

Review 7.  Anesthetics may modulate cancer surgical outcome: a possible role of miRNAs regulation.

Authors:  Masashi Ishikawa; Masae Iwasaki; Atsuhiro Sakamoto; Daqing Ma
Journal:  BMC Anesthesiol       Date:  2021-03-09       Impact factor: 2.217

Review 8.  Anesthetics and Long Term Cancer Outcomes: May Epigenetics Be the Key for Pancreatic Cancer?

Authors:  Zhirajr Mokini; Alessandro Cama; Patrice Forget
Journal:  Medicina (Kaunas)       Date:  2022-08-14       Impact factor: 2.948

9.  MicroRNA34a is associated with chemotherapy resistance, metastasis, recurrence, survival, and prognosis in patient with osteosarcoma.

Authors:  Hongyu Lian; Yang Zhou; Zhang Sun; Kexin Liu
Journal:  Medicine (Baltimore)       Date:  2022-09-23       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.